
    
      Patients are screened and must sign informed consent at visit 1. At the 2nd visit, all
      patients receive a baseline infusion of Natalizumab, which is followed by an 8 week washout
      Phase. After the washout Phase all patients receive fingolimod for 32 weeks.
    
  